Clinical trial

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

NCT01695954

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pitavastatin Normalized identity: pitavastatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Darunavir Normalized identity: darunavirView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Ritonavir Normalized identity: ritonavirView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Efavirenz Normalized identity: efavirenzView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-05-01

PhasePHASE1

Conditions

Hyperlipidemiaverified · MONDO: hyperlipidemia

HIVunresolved

Interventions

PitavastatinDRUG · verified · RxNorm: pitavastatin

DarunavirDRUG · verified · RxNorm: darunavir

RitonavirDRUG · verified · RxNorm: ritonavir

EfavirenzDRUG · verified · RxNorm: efavirenz

Sponsors & collaborators

NYU Langone Healthlead sponsor

New York City Health and Hospitals Corporationcollaborator

Kowa Pharmaceuticals America, Inc.collaborator

University at Buffalocollaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01695954 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.